Grifols (GRF) Q3 2025 earnings summary

Executive summary

• Year-to-date revenue reached EUR 5,542 million, up 7.7% year-over-year, with adjusted EBITDA of EUR 1,358 million, up 11.2% year-over-year and margin expansion to 24.5%.

• Free cash flow pre-M&A and pre-dividends improved by EUR 257 million year-over-year, reaching EUR 188 million year-to-date.

• Leverage ratio improved to 4.2x from 5.1x in the prior year, reflecting ongoing deleveraging.

• Strong demand in core franchises, especially immunoglobulins and Alpha-1, supported by commercial execution and innovation.

• Value Creation Plan focused on commercial growth, margin expansion, and pipeline execution remains central.

Financial highlights

• Q3 2025 net revenue was EUR 1,865 million, up 9.1% year-over-year at constant currency.

• Adjusted EBITDA for Q3 was EUR 482 million (25.8% margin), with year-to-date margin at 24.5%.

• Year-to-date group profit was EUR 304 million, up over 245% versus 2024.

• Free cash flow pre-M&A and pre-dividends for Q3 at EUR 203 million.

• Gross margin for Q3 was 39.3%, up 50bps year-over-year.

Outlook and guidance

• Revenue guidance for FY 2025 raised to above EUR 7,600 million at guidance FX rates.

• Adjusted EBITDA guidance reaffirmed at EUR 1,875–1,925 million.

• Free cash flow pre-M&A pre-dividends guidance improved to EUR 400–425 million.

• Full-year FX headwinds estimated at EUR 70 million for Adjusted EBITDA.

• Expect robust Q4, but absolute comparison to Q4 2024 will be less favorable due to prior phasing benefits.